Hematology Oncology Snippets

Share this post

User's avatar
Hematology Oncology Snippets
The DESTINY of Trastuzumab Deruxtecan

The DESTINY of Trastuzumab Deruxtecan

DESTINY Breast-03

Astha Thakkar's avatar
Astha Thakkar
Feb 15, 2023
∙ Paid
2

Share this post

User's avatar
Hematology Oncology Snippets
The DESTINY of Trastuzumab Deruxtecan
Share

Background:

HER2 positive breast cancer has seen some really sophisticated drugs come through in this space and the best example of this is the antibody-drug conjugate, trastuzumab-deruxtecan (T-dxd). It is smartly designed to have a high drug-to-antibody ratio of approximately 8 (compared to 3.5 for trastuzumab emtansine (T-DM1))that remains stable ther…

Keep reading with a 7-day free trial

Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Astha Thakkar
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share